Advertisement
Screener

Catheter Precision, Inc. (VTAK) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

1.8 / 5 stars · 21/60 Roast Me

Catheter Precision, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

Catheter Precision, Inc. (VTAK) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$26.86 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.

Discontinued › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-03-28

  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$8.16M.
  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$4.76M.
  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$8.45M.
  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$5.50M.
  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$26.86M.
  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$27.26M.
  • Catheter Precision, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$35.32M.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month
2022-12-31-$8.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28
-$12.92M
derived: sum of 2 quarters · filed 2023-03-28
-$21.37M
derived: sum of 3 quarters · filed 2023-03-28
-$26.86M
10-K · filed 2023-03-28
2022-09-30-$4.76M
10-Q · filed 2022-11-14
-$13.21M
derived: sum of 2 quarters · filed 2022-11-14
-$18.71M
10-Q · filed 2022-11-14
-$26.99M
derived: sum of 4 quarters · filed 2023-03-28
2022-06-30-$8.45M
10-Q · filed 2022-08-16
-$13.94M
10-Q · filed 2022-08-16
-$22.23M
derived: sum of 3 quarters · filed 2023-03-28
-$29.61M
derived: sum of 4 quarters · filed 2023-03-28
2022-03-31-$5.50M
10-Q · filed 2022-05-16
-$13.78M
derived: sum of 2 quarters · filed 2023-03-28
-$21.16M
derived: sum of 3 quarters · filed 2023-03-28
-$25.88M
derived: sum of 4 quarters · filed 2023-03-28
2021-12-31-$8.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28
-$15.66M
derived: sum of 2 quarters · filed 2023-03-28
-$20.38M
derived: sum of 3 quarters · filed 2023-03-28
-$27.26M
10-K · filed 2023-03-28
2021-09-30-$7.38M
10-Q · filed 2022-11-14
-$12.10M
derived: sum of 2 quarters · filed 2022-11-14
-$18.97M
10-Q · filed 2022-11-14
-$29.22M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$4.72M
10-Q · filed 2022-08-16
-$11.60M
10-Q · filed 2022-08-16
-$21.84M
derived: sum of 3 quarters · filed 2022-08-16
-$29.35M
derived: sum of 4 quarters · filed 2022-08-16
2021-03-31-$6.88M
10-Q · filed 2022-05-16
-$17.12M
derived: sum of 2 quarters · filed 2022-05-16
-$24.63M
derived: sum of 3 quarters · filed 2022-05-16
2020-12-31-$10.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24
-$17.76M
derived: sum of 2 quarters · filed 2022-03-24
-$35.32M
10-K · filed 2022-03-24
2020-09-30-$7.51M
10-Q · filed 2021-11-15
-$25.08M
10-Q · filed 2021-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
INVO Fertility, Inc. (IVF)United States$0.002B-0.71
NEXGEL, INC. (NXGL)United States$0.002B
Tenon Medical, Inc. (TNON)United States$0.002B
Profusa, Inc. (PFSA)United States$0.002B
Vivos Therapeutics, Inc. (VVOS)United States$0.003B-0.26
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
Autonomix Medical, Inc. (AMIX)United States$0.004B
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B